A detailed history of Royce & Associates LP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 323,924 shares of MXCT stock, worth $1.36 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
323,924
Previous 202,652 59.84%
Holding current value
$1.36 Million
Previous $794,000 58.69%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$3.68 - $5.06 $446,280 - $613,636
121,272 Added 59.84%
323,924 $1.26 Million
Q2 2024

Aug 13, 2024

BUY
$3.63 - $5.0 $440,043 - $606,120
121,224 Added 148.87%
202,652 $794,000
Q1 2024

May 13, 2024

SELL
$3.94 - $5.38 $968,885 - $1.32 Million
-245,910 Reduced 75.12%
81,428 $341,000
Q4 2023

Feb 12, 2024

SELL
$2.6 - $5.24 $247,577 - $498,963
-95,222 Reduced 22.53%
327,338 $1.54 Million
Q3 2023

Nov 09, 2023

BUY
$3.02 - $5.1 $71,815 - $121,277
23,780 Added 5.96%
422,560 $1.32 Million
Q2 2023

Aug 07, 2023

BUY
$3.69 - $5.35 $335,254 - $486,074
90,855 Added 29.51%
398,780 $1.83 Million
Q1 2023

May 04, 2023

BUY
$4.03 - $5.89 $152,334 - $222,642
37,800 Added 13.99%
307,925 $1.52 Million
Q4 2022

May 23, 2023

SELL
$4.92 - $7.4 $185,976 - $279,720
-37,800 Reduced 12.28%
270,125 $1.47 Million
Q4 2022

Feb 13, 2023

BUY
$4.92 - $7.4 $240,096 - $361,120
48,800 Added 22.05%
270,125 $1.48 Million
Q3 2022

Nov 03, 2022

BUY
$4.52 - $6.51 $489,628 - $705,195
108,325 Added 95.86%
221,325 $1.44 Million
Q2 2022

Aug 04, 2022

SELL
$3.59 - $6.81 $4.06 Million - $7.7 Million
-1,131,272 Reduced 90.92%
113,000 $534,000
Q1 2022

May 05, 2022

SELL
$5.26 - $10.84 $310,597 - $640,091
-59,049 Reduced 4.53%
1,244,272 $8.7 Million
Q4 2021

Feb 07, 2022

SELL
$8.87 - $12.94 $968,985 - $1.41 Million
-109,243 Reduced 7.73%
1,303,321 $13.3 Million
Q3 2021

Nov 10, 2021

BUY
$12.21 - $17.2 $17.2 Million - $24.3 Million
1,412,564 New
1,412,564 $17.2 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $426M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.